Key Points
- On Nov 17, Southpoint Capital Advisors LP sold 85,918 Fennec Pharmaceuticals (TSE:FRX) shares at an average price of C$12.35 for C$1,061,087.30, leaving it with 3,764,082 shares — a 2.23% reduction in its ownership.
- The firm has been repeatedly selling since Oct 7, offloading a total of 313,132 shares across five transactions (including 160,100 on Nov 14) for roughly C$3.74 million in proceeds, signaling sustained insider selling activity.
- FRX opened at C$10.60, trades in a 52‑week range of C$7.02–C$13.83, and has a market cap of about C$362 million, with a negative PE ratio and elevated beta reflecting higher risk/volatility.
Fennec Pharmaceuticals Inc. (TSE:FRX - Get Free Report) insider Southpoint Capital Advisors Lp sold 85,918 shares of the business's stock in a transaction on Monday, November 17th. The stock was sold at an average price of C$12.35, for a total value of C$1,061,087.30. Following the completion of the transaction, the insider directly owned 3,764,082 shares of the company's stock, valued at approximately C$46,486,412.70. This trade represents a 2.23% decrease in their ownership of the stock.
Southpoint Capital Advisors Lp also recently made the following trade(s):
- On Friday, November 14th, Southpoint Capital Advisors Lp sold 160,100 shares of Fennec Pharmaceuticals stock. The stock was sold at an average price of C$11.24, for a total value of C$1,799,524.00.
- On Tuesday, October 7th, Southpoint Capital Advisors Lp sold 26,900 shares of Fennec Pharmaceuticals stock. The stock was sold at an average price of C$13.23, for a total transaction of C$355,887.00.
- On Wednesday, October 8th, Southpoint Capital Advisors Lp sold 19,605 shares of Fennec Pharmaceuticals stock. The stock was sold at an average price of C$13.07, for a total transaction of C$256,237.35.
- On Thursday, October 9th, Southpoint Capital Advisors Lp sold 20,609 shares of Fennec Pharmaceuticals stock. The stock was sold at an average price of C$12.89, for a total value of C$265,650.01.
Fennec Pharmaceuticals Price Performance
FRX stock opened at C$10.60 on Friday. Fennec Pharmaceuticals Inc. has a fifty-two week low of C$7.02 and a fifty-two week high of C$13.83. The stock has a market cap of C$362.02 million, a PE ratio of -40.77 and a beta of 2.51. The firm's 50-day simple moving average is C$11.61 and its 200 day simple moving average is C$11.73. The company has a quick ratio of 10.17, a current ratio of 7.80 and a debt-to-equity ratio of -620.83.
About Fennec Pharmaceuticals
(
Get Free Report)
Fennec Pharmaceuticals Inc is a clinical-stage biotechnology company. It is primarily engaged in research and development activities. The company is developing Sodium Thiosulfate (STS), a chemo-protectant against hearing loss associated with platinum-based chemotherapy. Its lead product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin induced hearing loss, or ototoxicity in children.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
